These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21904312)

  • 1. Biotech on pace for record year.
    Yang W
    Nat Biotechnol; 2011 Sep; 29(9):780. PubMed ID: 21904312
    [No Abstract]   [Full Text] [Related]  

  • 2. 2007--a banner year for biotech.
    Lawrence S
    Nat Biotechnol; 2008 Feb; 26(2):150. PubMed ID: 18259162
    [No Abstract]   [Full Text] [Related]  

  • 3. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 4. Public biotech 2009-the numbers.
    Huggett B; Hodgson J; Lähteenmäki R
    Nat Biotechnol; 2010 Aug; 28(8):793-9. PubMed ID: 20697401
    [No Abstract]   [Full Text] [Related]  

  • 5. 2005: biotech partners up.
    Lawrence S
    Nat Biotechnol; 2006 Feb; 24(2):126. PubMed ID: 16465145
    [No Abstract]   [Full Text] [Related]  

  • 6. Public biotech 2007--the numbers.
    Lawrence S; Lähteenmäki R
    Nat Biotechnol; 2008 Jul; 26(7):753-62. PubMed ID: 18612294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biotech's wellspring: the health of private biotech in 2012.
    Huggett B
    Nat Biotechnol; 2013 May; 31(5):396-403. PubMed ID: 23657390
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech financing retrenches in Q2.
    Lawrence S
    Nat Biotechnol; 2006 Aug; 24(8):883. PubMed ID: 16900116
    [No Abstract]   [Full Text] [Related]  

  • 9. Biotech drug market steadily expands.
    Lawrence S
    Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
    [No Abstract]   [Full Text] [Related]  

  • 10. Public biotech 2013--the numbers.
    Lawrence S; Lahteenmaki R
    Nat Biotechnol; 2014 Jul; 32(7):626-32. PubMed ID: 25004227
    [No Abstract]   [Full Text] [Related]  

  • 11. Where the money is.
    Fitzgerald M
    Nat Biotechnol; 2006 Mar; 24(3):240-2. PubMed ID: 16525370
    [No Abstract]   [Full Text] [Related]  

  • 12. 2006: a stellar year for financing.
    Lawrence S
    Nat Biotechnol; 2007 Feb; 25(2):156. PubMed ID: 17287738
    [No Abstract]   [Full Text] [Related]  

  • 13. BioXell: an Italian biotech success story?
    Sheridan C
    Nat Biotechnol; 2006 Sep; 24(9):1045-6. PubMed ID: 16964198
    [No Abstract]   [Full Text] [Related]  

  • 14. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

  • 15. The biotech drug market.
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
    [No Abstract]   [Full Text] [Related]  

  • 16. Upward trend in financing continues, but fewer feel flush.
    Lawrence S
    Nat Biotechnol; 2007 Jan; 25(1):3. PubMed ID: 17211374
    [No Abstract]   [Full Text] [Related]  

  • 17. Deconstructing Myogen's market cap.
    Ransom J
    Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
    [No Abstract]   [Full Text] [Related]  

  • 18. IPOs break $1 billion in Q2.
    Lawrence S
    Nat Biotechnol; 2007 Aug; 25(8):833. PubMed ID: 17687349
    [No Abstract]   [Full Text] [Related]  

  • 19. Crystal gazing: biotech's financial outlook: the biotech analyst's view.
    Schmidt E
    Nat Biotechnol; 2006 Mar; 24(3):261-2. PubMed ID: 16525376
    [No Abstract]   [Full Text] [Related]  

  • 20. Taiwan biotech buoyed by colossal financings.
    Cyranoski D
    Nat Biotechnol; 2014 Jun; 32(6):508-10. PubMed ID: 24911482
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.